scholarly journals Effectiveness of Tranexamic Acid for Reducing Postpartum Blood Loss in the First Two Hours after Vaginal Delivery: A Randomised Controlled Trial

2018 ◽  
Author(s):  
Anuchat Sujita ◽  
Srisuda Songthamwat ◽  
Metha Songthamwat
Keyword(s):  
Randomised Controlled Trial ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Vaginal Delivery ◽  
Controlled Trial ◽  
Postpartum Blood Loss ◽  
Randomised Controlled

scholarly journals Study protocol: haemostatic efficacy and safety of preemptive antifibrinolysis with multidose intravenous tranexamic acid in elderly hip fracture patients: design of a prospective randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e047382
Author(s):  
Jiacheng Liu ◽  
Yiting Lei ◽  
Junyi Liao ◽  
Xi Liang ◽  
Ning Hu ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Randomised Controlled Trial ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Controlled Trial ◽  
Inflammatory Factors ◽  
Controlled Clinical Trial ◽  
Hip Fracture Surgery ◽  
Hidden Blood Loss ◽  
Randomised Controlled

IntroductionHip fracture surgery is often associated with substantial blood loss and a high allogeneic blood transfusion (ABT) rate. Preoperative hidden blood loss (HBL) has been observed clinically but there is little evidence for the efficacy of tranexamic acid (TXA) in controlling preoperative HBL. We designed a randomised controlled trial to evaluate the efficacy of preemptive antifibrinolysis with multidose intravenous TXA (IV-TXA) in reducing preoperative HBL in elderly patients with hip fractures.Methods and analysisThis is a prospective, randomised, placebo-controlled clinical trial. Patients older than 65 years diagnosed with primary unilateral femoral neck fracture or intertrochanteric fracture will be randomly assigned to group A (receiving 100 mL of intravenous normal saline every 12 hours preoperatively and 1.5 g of IV-TXA every 12 hours postoperatively for 3 days) or group B (receiving 1.5 g of IV-TXA every 12 hours preoperatively and 1.5 g of IV-TXA every 12 hours postoperatively for 3 days). The primary outcomes will be the hidden blood loss, haemoglobin decrease and ABT rate. The secondary outcomes include the levels of inflammatory factors (such as C reactive protein) and coagulation and fibrinolysis parameters (such as D-dimer). Other outcomes such as injury time, length of stay and hospitalisation expenses will also be compared between groups.Ethics and disseminationThis study has been approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. The findings of the study will be disseminated through peer-reviewed journals and conference presentations.Trial registration numberChiCTR2100045960.

Reducing blood loss in primary knee arthroplasty: A prospective randomised controlled trial of tranexamic acid and fibrin spray

The Knee ◽  
2012 ◽  
Vol 19 (4) ◽  
pp. 295-298 ◽  
Author(s):  
Jamie S. McConnell ◽  
Sandeep Shewale ◽  
Niall A. Munro ◽  
Kalpesh Shah ◽  
Angela H. Deakin ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Knee Arthroplasty ◽  
Controlled Trial ◽  
Primary Knee Arthroplasty ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document